Learning Zone
IFN-Gamma in Hyperinflammation: Key Insights
How might emerging evidence on treatment targets change the future treatment paradigm for people with macrophage activation syndrome (MAS), hemophagocytic lymphohistiocytosis (HLH), and Still’s disease? Find out more about the evolving understanding of the role of hyperinflammation in MAS, HLH, and Still’s disease with a range of resources, including:
- Highlights from the Paediatric Rheumatology European Society (PReS) 2024 congress symposium, including insights from Fabrizio De Benedetti, Fatma Dedeoglu, and Petter Brodin on inflammatory pathways, treatment targets, and patient experience
- Coming soon: Expert interview on late breakers presented at the American College of Rheumatology (ACR) Convergence 2024
Updates in your area
of interest
of interest
Articles your peers
are looking at
are looking at
Bookmarks
saved
saved
Days to your
next event
next event
This webpage content has been developed by EPG Health and sponsored by SobiTM. This educational activity is intended for healthcare professionals only.